Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priti Hegde

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Frontiers in Endocrinology|June 5, 2012
Prostate cancer - a biomarker perspectiveYanqiu Liu, Priti Hegde, Fengmin Zhang, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 8, 2020
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast CancerYijin Li, Bharathi Vennapusa, Ching-Wei Chang, et al.
Cellular Microbiology|October 9, 2003
More than just innate immunity: comparative analysis of Chlamydophila pneumoniae and Chlamydia trachomatis effects on host-cell gene regulationSimone Hess, Jan Peters, Gerda Bartling, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2020
Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancerYoshiro Itatani, Takamasa Yamamoto, Cuiling Zhong, et al.
Journal for Immunotherapy of Cancer|November 26, 2020
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancersMariya Rozenblit, Richard Huang, Natalie Danziger, et al.
Journal for Immunotherapy of Cancer|October 25, 2019
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumabLuciana Molinero, Yijin Li, Ching-Wei Chang, et al.
The Journal of Molecular Diagnostics : JMD|March 18, 2022
Driver Mutation Variant Allele Frequency in Circulating Tumor DNA and Association with Clinical Outcome in Patients with Non-Small Cell Lung Cancer and EGFR- and KRAS-Mutated TumorsMeijuan Li, Lei Yang, Jason Hughes, et al.
Cancer Discovery|March 6, 2012
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrenceDaniel V T Catenacci, Les Henderson, Shu-Yuan Xiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2006
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerWenle Xia, Sarah Bacus, Priti Hegde, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Frontiers in Endocrinology|June 5, 2012
Prostate cancer - a biomarker perspectiveYanqiu Liu, Priti Hegde, Fengmin Zhang, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 8, 2020
Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast CancerYijin Li, Bharathi Vennapusa, Ching-Wei Chang, et al.
Cellular Microbiology|October 9, 2003
More than just innate immunity: comparative analysis of Chlamydophila pneumoniae and Chlamydia trachomatis effects on host-cell gene regulationSimone Hess, Jan Peters, Gerda Bartling, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 21, 2020
Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancerYoshiro Itatani, Takamasa Yamamoto, Cuiling Zhong, et al.
Journal for Immunotherapy of Cancer|November 26, 2020
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancersMariya Rozenblit, Richard Huang, Natalie Danziger, et al.
Journal for Immunotherapy of Cancer|October 25, 2019
Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumabLuciana Molinero, Yijin Li, Ching-Wei Chang, et al.
The Journal of Molecular Diagnostics : JMD|March 18, 2022
Driver Mutation Variant Allele Frequency in Circulating Tumor DNA and Association with Clinical Outcome in Patients with Non-Small Cell Lung Cancer and EGFR- and KRAS-Mutated TumorsMeijuan Li, Lei Yang, Jason Hughes, et al.
Cancer Discovery|March 6, 2012
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrenceDaniel V T Catenacci, Les Henderson, Shu-Yuan Xiao, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 10, 2006
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancerWenle Xia, Sarah Bacus, Priti Hegde, et al.
Investigational New Drugs|March 8, 2014
A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumorsColin D Weekes, Muralidhar Beeram, Anthony W Tolcher, et al.
Pageof 3